Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Increase in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 800 shares, a growth of 700.0% from the March 31st total of 100 shares. Based on an average daily volume of 12,900 shares, the days-to-cover ratio is currently 0.1 days.

Bavarian Nordic A/S Trading Down 3.2 %

OTCMKTS:BVNRY opened at $6.92 on Friday. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 5.50 and a beta of 1.50. The firm has a fifty day simple moving average of $7.60 and a two-hundred day simple moving average of $7.59. Bavarian Nordic A/S has a 12 month low of $5.95 and a 12 month high of $10.65.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last posted its quarterly earnings results on Wednesday, March 6th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.12. The business had revenue of $353.27 million during the quarter, compared to analysts’ expectations of $340.71 million. Bavarian Nordic A/S had a net margin of 20.80% and a return on equity of 0.07%. Equities analysts predict that Bavarian Nordic A/S will post 0.52 earnings per share for the current fiscal year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.